Back to results
US 2014/0004555 A1Published application
Non-Transformed, Immortalized Human T-Lymphocyte Cell-Lines
AssigneeSouthern Methodist University
InventorsRobert Harrod, Megan M. Romeo
Life of this patent
Estimating the term…
Abstract
The present invention includes a composition and a method of making the same comprising a non-transformed, immortalized T-lymphocyte cell-line, wherein the T lymphocytes are IL-2 dependent and interact with an extracellular matrix.
Claims27
A composition comprising a non-transformed, immortalized T-lymphocyte cell-line, wherein the T lymphocytes are IL-2 dependent and interact with an extracellular matrix.
A method of making immortalized T cells comprising:
- obtaining peripheral blood mononuclear cells (PBMCs);
- transducing the peripheral blood mononuclear cells with a vector engineered to express a translation-optimized version of the HTLV-1 p30II oncoprotein;
- culturing the transduced PBMCs in the presence of Blasticidin;
- and
- passaging the transduced PBMCs beyond crisis in the presence of human recombinant IL-2 until immortalization.
2 more elements
A method of evaluating a candidate drug believed to be useful in treating a disease, the method comprising:
- (a) contacting the candidate drug with a non-transformed, immortalized T-lymphocyte cell-line, wherein the T lymphocytes are IL-2 dependent, interact with an extracellular matrix;
- and
- (b) monitoring the response by the T-lymphocyte cell-line to the candidate drug, wherein a relative and statistically significant activation or suppression of the T-lymphocyte cell-line indicates that the candidate drug is useful in modifying a T-lymphocyte response.
Dependencies are inferred from the claim text.